Impact of modified microbiology reporting on the treatment of low-risk AmpC Enterobacterales infections: a multi-centre controlled interrupted time series study
Journal of Antimicrobial Chemotherapy · 04.08.2026 · 81 (9)
DOI: 10.1093/jac/dkag269 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 04.08.2026. Verfasst von Marie-Félixe Granger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Temerty Faculty of Medicine, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Enterobacteriaceae Infections, Anti-Bacterial Agents, beta-Lactamases, Enterobacteriaceae. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Objectives
We assessed the impact of a modified microbiology report and cascade that selectively reported narrower-spectrum β-lactams for low-risk AmpC Enterobacterales (AmpC-E).
Methods
We conducted a controlled interrupted time series analysis to assess the proportion of patients receiving ceftriaxone or piperacillin/tazobactam on the fourth day of antibiotic treatment for low-risk AmpC-E infection (Serratia marcescens, Morganella morganii, Providencia spp., Citrobacter koseri) compared with a high-risk AmpC-E (Enterobacter cloacae complex, Klebsiella aerogenes, Citrobacter freundii) control group. Secondary outcomes included a pre-post measurement of antibiotic use on the fourth day of therapy, death at 30 days, and recurrent infection at 90 days.
Results
Patients with low-risk AmpC-E infections were more likely to receive ceftriaxone or piperacillin/tazobactam compared with high-risk AmpC-E controls [incidence rate ratio (IRR) 39.8, 95% CI 1.8–871.7, P = 0.02]. There was an upward shift and trend in ceftriaxone and piperacillin/tazobactam use during the implementation period in the low-risk AmpC-E group compared with the control group (IRR 3.3, 95% CI 0.9–11.9, P = 0.07 and slope 1.3, 95% CI 1.0–1.8, P = 0.10), with an associated reduction in fluoroquinolone use. During the implementation period, 30 day mortality (13.8% versus 12.1%, P = 0.70) and recurrent infection at 90 days (6.4% versus 5.7%, P = 0.83) were similar between low-risk and high-risk AmpC-E groups.
Conclusions
Modification of microbiology reporting for low-risk AmpC Enterobacterales infections to selectively report narrower-spectrum β-lactams resulted in a rapid and sustained increase in use of ceftriaxone and piperacillin/tazobactam across two hospitals. Aligning this microbiology reporting with guidelines would have scalable impact on hospital antimicrobial stewardship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
- Department of Pharmacy, Sunnybrook Health Sciences Centre, Toronto, Canada.
- Division of Infectious Diseases, Michael Garron Hospital, Toronto, Canada.
- Shared Hospital Laboratory, Toronto, Canada.
- Centre for Quality Improvement and Patient Safety, University of Toronto, Toronto, Canada.
- Division of Infectious Diseases, Sunnybrook Health Sciences Centre, Toronto, Canada.
Zitieren
APA
Granger, M. F., Elligsen, M., McCready, J., Li, X. X., Kozak, R. A., Leis, J. A., & Lam, P. W. (2026). Impact of modified microbiology reporting on the treatment of low-risk AmpC Enterobacterales infections: a multi-centre controlled interrupted time series study. Journal of Antimicrobial Chemotherapy, 81(9). https://doi.org/10.1093/jac/dkag269
Vancouver
Granger MF, Elligsen M, McCready J, Li XX, Kozak RA, Leis JA, et al. Impact of modified microbiology reporting on the treatment of low-risk AmpC Enterobacterales infections: a multi-centre controlled interrupted time series study. Journal of Antimicrobial Chemotherapy. 2026;81(9). doi:10.1093/jac/dkag269
BibTeX
@article{Granger2026,
author = {Granger, Marie-Félixe and Elligsen, Marion and McCready, Janine and Li, Xena X and Kozak, Robert A and Leis, Jerome A and Lam, Philip W},
title = {Impact of modified microbiology reporting on the treatment of low-risk AmpC Enterobacterales infections: a multi-centre controlled interrupted time series study},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {9},
doi = {10.1093/jac/dkag269}
}
EUVIMED